Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

p53 gene therapy - Shenzhen SiBiono GeneTech

Drug Profile

p53 gene therapy - Shenzhen SiBiono GeneTech

Alternative Names: Gendicine; p53 gene therapy - SiBiono; rAD-p53 - Shenzhen SiBiono GenTech; Recombinant Ad-p53 anti-cancer injection - Sibiono

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen SiBiono GeneTech
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene transference; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Head and neck cancer
  • Phase II Liver cancer
  • Preclinical Urogenital cancer

Most Recent Events

  • 25 Sep 2019 Preclinical trials in Urogenital cancer in China (unspecified route)
  • 25 Sep 2019 Preclinical pharmacodynamics data in Urogenital cancer presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2019)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in India (Intratumoural, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top